Physician profile
Terry Smith
NPI 1821539255
$1,308.71
in general payments reported to CMS, 2019-2025
19 companies · $15.77 in 2025
The $15.77 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $111 · 2022: $430 · 2023: $728 · 2024: $23.27 · 2025: $15.77.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $759 · Education: $8.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $758.56 |
| Education | $8.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $302.12 | 2021-2023 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $151.43 | 2021-2023 | |
| Abbott Laboratories | $106.79 | 2021-2023 | Freestyle Libre 3 |
| Biohaven Pharmaceutical Holding Company LTD. | $105.96 | 2022 | |
| Boston Scientific Corporation | $105.74 | 2022-2024 | Watchman Flx, Wavewriter Alpha Prime 16 |
| Lilly USA, LLC | $100.14 | 2022-2023 | Mounjaro, Trulicity |
| Janssen Pharmaceuticals, INC | $76.43 | 2023 | Spravato |
| Bayer Healthcare Pharmaceuticals INC. | $55.69 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $51.54 | 2022-2025 | Airsupra, Farxiga |
| Otsuka America Pharmaceutical, INC. | $41.83 | 2023 | Rexulti |
| Exact Sciences Corporation | $40.71 | 2023 | Cologuard Collection Kit |
| Pfizer INC. | $39.75 | 2023 | |
| Amgen INC. | $31.92 | 2021-2023 | Repatha, Otezla |
| Inspire Medical Systems, INC. | $21.18 | 2023 | Inspire |
| Sanofi-Aventis U.S. LLC | $17.07 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.72 | 2021 | |
| Merck Sharp & Dohme LLC | $15.00 | 2023 | Belsomra |
| Ultragenyx Pharmaceutical INC. | $14.52 | 2021 | |
| Novartis Pharmaceuticals Corporation | $14.17 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Terry Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.